AIM ImmunoTech Inc. (AIM)
NYSEAMERICAN: AIM · Real-Time Price · USD
0.1436
-0.0050 (-3.36%)
At close: Nov 13, 2026, 4:00 PM EST
0.1536
+0.0100 (6.96%)
After-hours: Nov 13, 2026, 6:56 PM EST
AIM ImmunoTech Employees
As of December 31, 2025, AIM ImmunoTech had 21 total employees, including 19 full-time and 2 part-time employees. The number of employees decreased by 2 or 8.70% compared to the previous year. That makes AIM ImmunoTech the 38,212th largest employer in the world and 5,458th in the United States.
Employees
21
Change (1Y)
-2
Growth (1Y)
-8.70%
Revenue / Employee
$4,333
Profits / Employee
-$672,810
Market Cap
4.37M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 21 | -2 | -8.70% | 19 | 2 |
| Dec 31, 2024 | 23 | -5 | -17.86% | 21 | 2 |
| Dec 31, 2023 | 28 | 4 | 16.67% | 26 | 2 |
| Dec 31, 2022 | 24 | 1 | 4.35% | 22 | 2 |
| Dec 31, 2021 | 23 | 0 | - | 21 | 2 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Senti Biosciences Holdings | 39 |
| Imunon | 20 |
| NuCana | 12 |
| Can-Fite BioPharma | 5 |
| Creative Medical Technology Holdings | 4 |
| Xenetic Biosciences | 2 |
| PharmaCyte Biotech | 2 |
| Pulmatrix | 2 |
AIM News
- 11 hours ago - AIM ImmunoTech Approaches Major Clinical Inflection Point with Phase 2 Pancreatic Cancer Data Expected Q1 2027; Reports Third Quarter 2026 Financial Results - GlobeNewsWire
- 1 day ago - AIM ImmunoTech Quarterly report: Q3 2026 - Filings
- 3 days ago - AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series - GlobeNewsWire
- 8 days ago - AIM ImmunoTech Highlights Ampligen® Opportunity to Potentially Extend Benefits of RAS-Targeted Therapies in Pancreatic Cancer - GlobeNewsWire
- 10 days ago - AIM ImmunoTech Proxy statement: Proxy filing - Filings
- 5 weeks ago - AIM ImmunoTech's Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdays - GlobeNewsWire
- 5 weeks ago - AIM ImmunoTech Highlights Recent Media Coverage of Ampligen's® Broad-Spectrum Antiviral and Biodefense Potential - GlobeNewsWire
- 6 weeks ago - AIM ImmunoTech Spotlights Growing Attention Around Ampligen® Pancreatic Cancer Strategy as DURIPANC Advances Toward Topline Data - GlobeNewsWire